Genfit S.A. (GNFT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jean-Francois Mouney | Co-Founder & Chairman of the Board | 433.58k | -- | 1955 |
| Mr. M. Pascal Prigent | Chief Executive Officer | 705.46k | -- | 1969 |
| Prof. Bart Staels | Co-Founder & Chairman of the Scientific Advisory Board | -- | -- | 1963 |
| Mr. Thomas Baetz | Chief Financial Officer | -- | -- | 1974 |
| Mr. Pascal Caisey | Chief Operating Officer | -- | -- | 1968 |
| Dr. Dean W. Hum Ph.D. | Chief Scientific Officer | 805.25k | -- | 1962 |
| Mr. Jean-Christophe Marcoux | Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG | -- | -- | 1978 |
| Mr. Laurent Lannoo | Corporate Secretary & Director of Legal Affairs | -- | -- | 1971 |
| Ms. Stefanie Magner J.D. | Chief Compliance Officer & Executive VP of International Legal Affairs | -- | -- | 1981 |
| Ms. Emilie Desodt | Executive Vice President of Human Resources | -- | -- | 1983 |
Genfit S.A.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 180
Description
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Corporate Governance
Upcoming Events
May 22, 2025 at 10:59 AM UTC
Genfit S.A. Earnings Date